Patents Assigned to Hikma Pharmaceuticals
-
Patent number: 11771663Abstract: The present invention is directed to epinephrine spray formulations. The present invention is further directed to methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatments.Type: GrantFiled: March 2, 2021Date of Patent: October 3, 2023Assignee: Hikma Pharmaceuticals USA Inc.Inventors: Thrimoorthy Potta, Craig Bastian, Ningxin Yan, Venkat Goskonda, Chandeshwari Chilampalli, Rachana Inavolu, Eshwaran Narayanan
-
Patent number: 11744811Abstract: The present invention is directed to methods of stabilizing a pharmaceutical composition comprising epinephrine containing the steps filling a container, capping the container, assembling the container and placing the assembled capped container (assembled device) in a secondary packaging system.Type: GrantFiled: June 30, 2021Date of Patent: September 5, 2023Assignee: Hikma Pharmaceuticals USA Inc.Inventors: Eshwaran Narayanan, Rajesh Wakaskar, Chandeshwari Chilampalli, Thrimoorthy Potta, Venkat R. Goskonda
-
Patent number: 11738011Abstract: The stable liquid formulations for parenteral administration include fentanyl or a pharmaceutically acceptable salt thereof. The formulations include a diluent and buffer, either containing sodium, in an aqueous solution that has a pH of about 3 to about 4.5. The parenteral liquid formulations are stable formulations that are supplied as a ready-to-administer product in an infusion container or bag. The stable formulations are terminally sterilized in the infusion container. The stable formulations are suitable for administration to a patient in need of therapy with fentanyl or a pharmaceutically acceptable salt thereof.Type: GrantFiled: November 17, 2021Date of Patent: August 29, 2023Assignee: HIKMA PHARMACEUTICALS INTERNATIONAL LIMITEDInventors: Andrew Conrad, Ragheb Al-Shakhshir, Ragheb AbuRmaileh
-
Patent number: 11684573Abstract: A liquid pharmaceutical composition for intravenous administration that includes vasopressin or a pharmaceutically acceptable salt thereof. The formulation further includes a lactate buffer or lactic acid, optionally in combination with a pH adjuster. The pharmaceutical composition can have a pH of from about 3.0 to about 4.1 and demonstrates improved stability for long term storage, particularly at room temperature.Type: GrantFiled: June 16, 2020Date of Patent: June 27, 2023Assignee: HIKMA PHARMACEUTICALS USA INC.Inventors: Gyongyi Szakalas-Gratzl, Ping Ma, James Murtagh
-
Patent number: 11628139Abstract: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.Type: GrantFiled: March 11, 2021Date of Patent: April 18, 2023Assignee: Hikma Pharmaceuticals USA Inc.Inventors: Kiran Amancha, Chandeshwari Chilampalli, Thrimoorthy Potta, Ningxin Yan, Venkat R. Goskonda
-
Patent number: 11617713Abstract: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.Type: GrantFiled: March 11, 2021Date of Patent: April 4, 2023Assignee: Hikma Pharmaceuticals USA Inc.Inventors: Kiran Amancha, Chandeshwari Chilampalli, Thrimoorthy Potta, Ningxin Yan, Venkat R. Goskonda
-
Patent number: 11571384Abstract: The present invention is directed to epinephrine spray formulations. The present invention is further directed to methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatments.Type: GrantFiled: June 13, 2018Date of Patent: February 7, 2023Assignee: Hikma Pharmaceuticals USA Inc.Inventors: Thrimoorthy Potta, Craig Bastian, Ningxin Yan, Venkat Goskonda, Chandeshwari Chilampalli, Rachana Inavolu, Eshwaran Narayanan
-
Patent number: 11517525Abstract: The present invention is directed to epinephrine spray formulations. The present invention is further directed to methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatments.Type: GrantFiled: June 13, 2018Date of Patent: December 6, 2022Assignee: Hikma Pharmaceuticals USA Inc.Inventors: Thrimoorthy Potta, Craig Bastian, Ningxin Yan, Venkat Goskonda, Chandeshwari Chilampalli, Rachana Inavolu, Eshwaran Narayanan
-
Patent number: 11471400Abstract: This invention relates to a dilute, ready-to-use solution of phenylephrine hydrochloride having improved stability and utility. In a particular embodiment, the formulation consists of an injectable form of phenylephrine hydrochloride with edetate disodium chelating agent in place of any sodium metabisulfite antioxidants to improve the solution's ability to remain stable and active in a dilute state after prolonged storage. This invention also relates to a form for injection of the solution that includes packaging the solution in a single-use container, as well as a form for containing the ready-to-use solution in a sterile, sealed container. Lastly this invention relates to methods of making the injectable solution for use in a single-use container, as well as for containment in a sterile, sealed container.Type: GrantFiled: October 6, 2021Date of Patent: October 18, 2022Assignee: Hikma Pharmaceuticals International LimitedInventors: David E. McAnany, Michael G. Parker, Sarah D. McCue
-
Patent number: 11433072Abstract: Stable and bioavailable oral dosage forms of ibrutinib, the dosage forms comprising ibrutinib and an acidifying agent. The dosage forms can further comprise a binder, such as sodium alginate, a surfactant, a lubricant, a filler and/or a disintegrant. Methods of treating cancers, particularly blood cancers, and graft versus host disease comprising administering to a patient in need thereof a dosage form comprising ibrutinib and an acidifying agent.Type: GrantFiled: June 10, 2021Date of Patent: September 6, 2022Assignee: HIKMA PHARMACEUTICALS USA, INC.Inventors: Mahmoud Ghannam, Shahin Fesharaki, Mohammad Al Hreebat, Ahmad Arif Mohammad
-
Patent number: 11213480Abstract: This invention relates to a dilute, ready-to-use solution of phenylephrine hydrochloride having improved stability and utility. In a particular embodiment, the formulation consists of an injectable form of phenylephrine hydrochloride with edetate disodium chelating agent in place of any sodium metabisulfite antioxidants to improve the solution's ability to remain stable and active in a dilute state after prolonged storage. This invention also relates to a form for injection of the solution that includes packaging the solution in a single-use container, as well as a form for containing the ready-to-use solution in a sterile, sealed container. Lastly this invention relates to methods of making the injectable solution for use in a single-use container, as well as for containment in a sterile, sealed container.Type: GrantFiled: August 5, 2016Date of Patent: January 4, 2022Assignee: Hikma Pharmaceuticals International LimitedInventors: David E. McAnany, Michael G. Parker, Sarah D. McCue
-
Patent number: 11207309Abstract: The stable liquid formulations for parenteral administration include fentanyl or a pharmaceutically acceptable salt thereof. The formulations include a diluent and buffer, either containing sodium, in an aqueous solution that has a pH of about 3 to about 4.5. The parenteral liquid formulations are stable formulations that are supplied as a ready-to-administer product in an infusion container or bag. The stable formulations are terminally sterilized in the infusion container. The stable formulations are suitable for administration to a patient in need of therapy with fentanyl or a pharmaceutically acceptable salt thereof.Type: GrantFiled: October 31, 2019Date of Patent: December 28, 2021Assignee: Hikma Pharmaceuticals International LimitedInventors: Andrew Conrad, Ragheb Al-Shakhshir, Ragheb AbuRmaileh
-
Patent number: 11135155Abstract: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.Type: GrantFiled: October 31, 2018Date of Patent: October 5, 2021Assignee: Hikma Pharmaceuticals USA Inc.Inventors: Kiran Amancha, Chandeshwari Chilampalli, Thrimoorthy Potta, Ningxin Yan, Venkat R. Goskonda
-
Patent number: 11077075Abstract: The present invention is directed to methods of stabilizing a pharmaceutical composition comprising epinephrine containing the steps filling a container, capping the container, assembling the container and placing the assembled capped container (assembled device) in a secondary packaging system.Type: GrantFiled: January 8, 2019Date of Patent: August 3, 2021Assignee: HIKMA PHARMACEUTICALS USA INC.Inventors: Eshwaran Narayanan, Rajesh Wakaskar, Chandeshwari Chilampalli, Thrimoorthy Potta, Venkat R. Goskonda
-
Patent number: 11053037Abstract: A medical vial filling system is adapted to fill a medical vial with a solution and cap the filled medical vial. A purging system includes a manifold disposed between a filling station and a capping station. The manifold includes a filling inlet port and a plurality of output ports. The output ports are positioned in a space proximate the filling station and in a space over the transport mechanism. A stoppering block includes a capping chamber for receiving a bushing positioned at the capping station. The stoppering block comprises a stoppering inlet port, a first nozzle opening into the capping chamber and a second nozzle extending into the capping chamber and directed into the medical vial when the medical vial is position in the capping station.Type: GrantFiled: August 29, 2018Date of Patent: July 6, 2021Assignee: HIKMA PHARMACEUTICALS USA INC.Inventors: Simon Freed, David C. Woodruff
-
Patent number: 10973814Abstract: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.Type: GrantFiled: November 5, 2019Date of Patent: April 13, 2021Assignee: HIKMA PHARMACEUTICALS USA INC.Inventors: Kiran Amancha, Chandeshwari Chilampalli, Thrimoorthy Potta, Ningxin Yan, Venkat R. Goskonda
-
Patent number: 10973781Abstract: The present invention is directed to epinephrine spray formulations. The present invention is further directed to methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatments.Type: GrantFiled: March 1, 2019Date of Patent: April 13, 2021Assignee: HIKMA PHARMACEUTICALS USA INC.Inventors: Thrimoorthy Potta, Craig Bastian, Ningxin Yan, Venkat Goskonda, Chandeshwari Chilampalli, Rachana Inavolu, Eshwaran Narayanan
-
Patent number: 10966925Abstract: The present invention is directed to epinephrine spray formulations. The present invention is further directed to methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatments.Type: GrantFiled: January 4, 2019Date of Patent: April 6, 2021Assignee: HIKMA PHARMACEUTICALS USA INC.Inventors: Thrimoorthy Potta, Craig Bastian, Ningxin Yan, Venkat Goskonda, Chandeshwari Chilampalli, Rachana Inavolu, Eshwaran Narayanan
-
Patent number: 10874658Abstract: Sublingual formulations containing an opioid, preferably, fentanyl or a pharmaceutically acceptable salt or ester thereof, naloxone or a pharmaceutically acceptable salt or ester thereof, and a terpene; as well as methods of treating pain by administering the formulations of the invention to a patient in need thereof.Type: GrantFiled: March 12, 2019Date of Patent: December 29, 2020Assignee: HIKMA PHARMACEUTICALS USA INC.Inventors: Ning Shan, Rajesh R. Wakaskar, Edwin A. Baldwin, Andrew B. Schlinkert, Min Wu, Ningxin Yan
-
Patent number: 10722510Abstract: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention both intranasally and sublingually to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally and sublingually the naloxone formulations of the present invention.Type: GrantFiled: August 17, 2016Date of Patent: July 28, 2020Assignee: HIKMA PHARMACEUTICALS USA INC.Inventors: Kiran Amancha, Shivani Chilampalli, Thrimoorthy Potta, Ningxin Yan, Venkat R. Goskonda